Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan

Stock Track

Feb 13, 2025

Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.

The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.

Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142639987"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142639987\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142639987?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142639987","market":"hk","top_or_hot":-1,"title":"Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan","media":"Stock Track","content":"<p>Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.</p>\n\n<p>The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.</p>\n\n<p>Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.</p>\n\n<p>The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.</p>\n\n<p>Ascendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"","article_id":"1142639987","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142639987","pubTimestamp":1739396320,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ascendis Pharma A/S  shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.The Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares . It also plans to net settle certain Restricted Stock Units  for around $9 million, preserving a total of approximately 200,000 ADSs held as treasur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"股票追踪Ascendis Pharma因第四季度业绩和回购计划盘后飙升6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1},"content_text":"Ascendis Pharma A/S (ASND) shares surged 6.03% in after-hours trading on Wednesday, following the company's better-than-expected fourth quarter 2024 earnings and revenue fueled by robust sales of its products SKYTROFA and YORVIPATH.\nThe Danish drugmaker announced a share repurchase program of up to $18.25 million to buy back its American Depositary Shares (ADSs). It also plans to net settle certain Restricted Stock Units (RSUs) for around $9 million, preserving a total of approximately 200,000 ADSs held as treasury shares.\nAscendis reported Q4 2024 revenue of €173.9 million, beating estimates of €111.2 million, driven by strong demand for its growth hormone deficiency treatment SKYTROFA and hypoparathyroidism drug YORVIPATH. The company expressed confidence in continued strong revenue growth, aided by potential label expansions and new product launches in the pipeline, including its TransCon CNP drug for achondroplasia in children.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"buyback,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}